Elevated IgG and IgM Autoantibodies to Advanced Glycation End Products of Vascular Elastin in Hypertensive Patients with Type 2 Diabetes: Relevance to Disease Initiation and Progression

被引:4
|
作者
Kostov, Krasimir [1 ]
Blazhev, Alexander [2 ]
机构
[1] Med Univ Pleven, Dept Pathophysiol, 1 Kliment Ohridski Str, Pleven 5800, Bulgaria
[2] Med Univ Pleven, Dept Biol, 1 Kliment Ohridski Str, Pleven 5800, Bulgaria
关键词
hypertension; type; 2; diabetes; advanced glycation end products (AGEs); autoantibodies to AGEs of vascular elastin; ACUTE-PHASE REACTANTS; C-REACTIVE PROTEIN; MATRIX METALLOPROTEINASE-2; ANTIBODIES; ASSOCIATION; ENDPRODUCTS; RECEPTOR; INFLAMMATION; LYMPHOCYTES; RETINOPATHY;
D O I
10.3390/pathophysiology29030034
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The increased glycation of elastin is an important factor in vascular changes in diabetes. Using the ELISA method, we determined serum levels of IgM and IgG autoantibodies to advanced glycation end products of vascular elastin (anti-AGE EL IgM and anti-AGE EL IgG) in 59 hypertensive patients with type 2 diabetes (T2D) and 20 healthy controls. Serum levels of matrix metalloproteinases-2 and -9 (MMP-2 and MMP-9) and the C-reactive protein (CRP) were also determined. The levels of anti-AGE EL IgM antibodies in the T2D group were similar to those in the control group, while those of anti-AGE EL IgG antibodies were significantly higher (p = 0.017). Significant positive correlations were found between the levels of anti-AGE EL IgM antibodies and MMP-2 (r = 0.322; p = 0.013) and between the levels of anti-AGE EL IgG antibodies and CRP (r = 0.265; p = 0.042). Our study showed that elevated anti-AGE EL IgG antibody levels may be an indicator of the enhanced AGE-modification and inflammatory-mediated destruction of vascular elastin in hypertensive patients with T2D. Anti-AGE EL IgM antibodies may reflect changes in vascular MMP-2 activity, and their elevated levels may be a sign of early vascular damage.
引用
收藏
页码:426 / 434
页数:9
相关论文
共 50 条
  • [21] Association of Advanced Glycation End Products With Lower-Extremity Atherosclerotic Disease in Type 2 Diabetes Mellitus
    Ying, Lingwen
    Shen, Yun
    Zhang, Yang
    Wang, Yikun
    Liu, Yong
    Yin, Jun
    Wang, Yufei
    Yin, Jingrong
    Zhu, Wei
    Bao, Yuqian
    Zhou, Jian
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [22] Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes
    Nakamura, N
    Yamazaki, K
    Satoh, A
    Urakaze, M
    Kobayashi, M
    Yamabe, H
    Osawa, H
    Shirato, K
    Sugawara, T
    Nakamura, M
    Tamura, M
    Okumura, K
    IN VIVO, 2003, 17 (02): : 177 - 180
  • [23] Assessment of Pentosidine as a Marker for Advanced Glycation End Products in Type 2 Diabetes Mellitus Patients
    Jaishankar, Sarath Kumar Jaganathan
    Murali, Amrutha
    Marzooka, Amrin
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2020, 14 (02)
  • [24] Excess body fat increases the accumulation of advanced glycation end products in the skin of patients with type 1 diabetes
    Zawada, Agnieszka Ewa
    Naskret, Dariusz
    Niedzwiecki, Pawel
    Grzymislawski, Marian
    Zozulinska-Ziolkiewicz, Dorota Anna
    Dobrowolska, Agnieszka
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 29 (10): : 1193 - 1199
  • [25] Susceptibility of six polymorphisms in the receptor for advanced glycation end products to type 2 diabetes: a systematic review and meta-analysis
    Cheng, Hao
    Zhu, Wenbin
    Zhu, Mou
    Sun, Yan
    Sun, Xiaojie
    Jia, Di
    Yang, Chao
    Yu, Haitao
    Zhang, Chunjing
    ENDOCRINE JOURNAL, 2021, 68 (08) : 993 - 1010
  • [26] Advanced glycation end-products and advanced oxidation protein products levels are correlates of duration of type 2 diabetes
    Heidari, Firouzeh
    Rabizadeh, Soghra
    Rajab, Armin
    Heidari, Farrokh
    Mouodi, Marjan
    Mirmiranpour, Hossien
    Esteghamati, Alireza
    Nakhjavani, Manouchehr
    LIFE SCIENCES, 2020, 260
  • [27] Relationship of serum advanced glycation end products with deterioration of periodontitis in type 2 diabetes patients
    Takeda, Munehiro
    Ojima, Miki
    Yoshioka, Hideo
    Inaba, Hiroaki
    Kogo, Mikihiko
    Shizukuishi, Satoshi
    Nomura, Makoto
    Amano, Atsuo
    JOURNAL OF PERIODONTOLOGY, 2006, 77 (01) : 15 - 20
  • [28] Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease
    Bakker, S. F.
    Tushuizen, M. E.
    Gozutok, E.
    Ciftci, A.
    Gelderman, K. A.
    Mulder, C. J.
    Simsek, S.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2015, 25 (02) : 230 - 235
  • [29] Role of Advanced Glycation End Products on Aortic Calcification in Patients with Type 2 Diabetes Mellitus
    Sanchis, Pilar
    Rivera, Rosmeri
    Fortuny, Regina
    Rio, Carlos
    Mas-Gelabert, Miguel
    Gonzalez-Freire, Marta
    Grases, Felix
    Masmiquel, Luis
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 16
  • [30] Relationship between advanced glycation end-products and advanced oxidation protein products in patients with type 2 diabetes with and without albuminuria: A cross-sectional survey
    Larry, Mehrdad
    Rabizadeh, Soghra
    Mohammadi, Fatemeh
    Yadegar, Amirhossein
    Jalalpour, Azadeh
    Mirmiranpour, Hossein
    Farahmand, Ghasem
    Esteghamati, Alireza
    Nakhjavani, Manouchehr
    HEALTH SCIENCE REPORTS, 2024, 7 (10)